Two Sigma Securities LLC Makes New $509,000 Investment in Novartis AG $NVS

Two Sigma Securities LLC bought a new position in Novartis AG (NYSE:NVS) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 3,246 shares of the company’s stock, valued at approximately $509,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. J.W. Cole Advisors Inc. boosted its holdings in Novartis by 0.6% in the fourth quarter. J.W. Cole Advisors Inc. now owns 10,577 shares of the company’s stock worth $1,348,000 after purchasing an additional 64 shares during the period. Roundview Capital LLC raised its holdings in shares of Novartis by 2.5% during the fourth quarter. Roundview Capital LLC now owns 2,711 shares of the company’s stock worth $374,000 after purchasing an additional 66 shares during the period. CPC Advisors LLC lifted its position in shares of Novartis by 4.6% in the 2nd quarter. CPC Advisors LLC now owns 1,516 shares of the company’s stock worth $238,000 after buying an additional 66 shares during the last quarter. IMA Advisory Services Inc. lifted its position in shares of Novartis by 10.9% in the 4th quarter. IMA Advisory Services Inc. now owns 710 shares of the company’s stock worth $98,000 after buying an additional 70 shares during the last quarter. Finally, Moody National Bank Trust Division boosted its holdings in shares of Novartis by 4.2% in the 2nd quarter. Moody National Bank Trust Division now owns 1,802 shares of the company’s stock valued at $282,000 after buying an additional 72 shares during the period. 13.12% of the stock is owned by institutional investors and hedge funds.

More Novartis News

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: Remibrutinib cleared two Phase III multiple sclerosis trials. The oral drug significantly reduced annualized relapse rates versus teriflunomide (Aubagio) in relapsing multiple sclerosis and also showed favorable results on MRI lesion measures. Novartis said a combined analysis indicated a clinically meaningful delay in disability progression, strengthening the drug’s potential commercial profile and supporting plans for global regulatory submissions. Novartis oral multiple sclerosis drug meets main goal in late stage studies
• Positive Sentiment: The positive MS data are viewed as an important growth catalyst. Analysts and investors see remibrutinib as a potential future blockbuster in a large market, particularly because it outperformed an established treatment and reportedly showed no liver-safety signal. The results prompted a sharp prior-session rally and could improve confidence in Novartis’ longer-term product pipeline. Novartis’ Remibrutinib Delivers Positive Results in Late-Stage MS Studies
• Positive Sentiment: Novartis signed a potential $3.2 billion Hybrozyme agreement with Alteogen. The deal could expand access to Alteogen’s drug-delivery technology and support development or commercialization of future medicines, though the financial commitment and deal milestones may limit the near-term earnings benefit. Novartis Signs Up To $3.2B Hybrozyme Deal With Alteogen
• Neutral Sentiment: Novartis plans to relocate laboratory activities and shut down some Basel production operations, potentially affecting about 130 jobs. The restructuring may improve efficiency over time but creates near-term execution and employee-transition costs. Novartis could cut about 130 jobs in Basel site relocation
• Negative Sentiment: Novartis paused eight autoimmune and neurological cell-therapy trials after three patient deaths. The pauses raise safety, regulatory and development risks for the experimental rap-cel program and prompted a customer-related setback for Oxford BioMedica, though the issue is separate from remibrutinib. Novartis pauses autoimmune cell therapy studies after deaths

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Novartis in a report on Friday, July 24th. Citigroup restated a “buy” rating on shares of Novartis in a research note on Wednesday, July 22nd. Seven research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $141.20.

Novartis Trading Up 0.7%

NYSE:NVS opened at $162.42 on Thursday. Novartis AG has a 1 year low of $121.57 and a 1 year high of $170.46. The stock has a market cap of $309.93 billion, a price-to-earnings ratio of 24.50, a PEG ratio of 3.14 and a beta of 0.45. The business has a fifty day moving average of $155.48 and a 200-day moving average of $153.74. The company has a debt-to-equity ratio of 0.89, a quick ratio of 0.67 and a current ratio of 0.86.

Novartis (NYSE:NVS) last issued its quarterly earnings data on Tuesday, June 30th. The company reported $2.41 earnings per share for the quarter. The business had revenue of $14.95 billion for the quarter. Novartis had a net margin of 23.29% and a return on equity of 38.56%. Equities analysts predict that Novartis AG will post 8.84 earnings per share for the current year.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.